Eurofins Scient (OTCMKTS:ERFSF) Reaches New 52-Week High – Time to Buy?

Eurofins Scient (OTCMKTS:ERFSF) reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $86.20 and last traded at $83.00, with a volume of 2541 shares. The stock had previously closed at $85.7720.

Analyst Ratings Changes

ERFSF has been the subject of a number of research analyst reports. BNP Paribas Exane upgraded Eurofins Scient to an “outperform” rating in a research note on Monday, January 5th. Citigroup reaffirmed a “neutral” rating on shares of Eurofins Scient in a report on Wednesday, October 22nd. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Eurofins Scient in a research report on Wednesday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy”.

Eurofins Scient Trading Up 1.6%

The company’s 50-day moving average is $75.53 and its 200 day moving average is $74.48. The company has a current ratio of 1.26, a quick ratio of 1.19 and a debt-to-equity ratio of 0.77.

Eurofins Scient Company Profile

Eurofins Scientific is a global provider of bioanalytical testing and laboratory services, offering a wide array of testing solutions to pharmaceutical, food, environmental, agriscience and consumer products industries. Its core services include pharmaceutical quality control, environmental testing for water and air quality, food safety analysis, agrochemical trials and clinical diagnostic support. The company operates specialized laboratories equipped with advanced analytical technologies such as chromatography, mass spectrometry and molecular biology to ensure compliance with regulatory standards and to support research and development efforts across multiple sectors.

Founded in 1987 by Gilles Martin and headquartered in Luxembourg, Eurofins has grown through a combination of organic expansion and strategic acquisitions.